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Abstract
Recognition of carbohydrates by antibodies can be affected by antigen composition and density. 
This had been investigated in a variety of controllable multivalent systems using synthetic 
carbohydrate antigens, yet such effects on anticarbohydrate antibodies in circulating human serum 
have not been fully addressed thus far. All humans develop a polyclonal and diverse response 
against carbohydrates containing a nonhuman sialic acid form, N-glycolylneuraminic acid 
(Neu5Gc). This red meat-derived monosaccharide is incorporated into a diverse collection of 
human glycans resulting in circulating anti-Neu5Gc antibodies in human sera. Such antibodies can 
cause exacerbation of diseases mediated by chronic inflammation such as cancer and 
atherosclerosis. We aimed to evaluate how different presentation modes of Neu5Gc-glycans can 
affect the detection of anti-Neu5Gc IgGs in human serum. Here, we compare serum IgG 
recognition of Neu5Gc-containing glycoproteins, glycopeptides, and synthetic glycans. First, 
Neu5Gc-positive or Neu5Gc-deficient mouse strains were used to generate glycopeptides from 
serum glycoproteins. Then we developed a reproducible ELISA to screen human sera against 
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evaluated ELISA screens against glycopeptides in comparison with glycoproteins, as well as 
against elaborated arrays displaying synthetic Neu5Gc-glycans. Our results demonstrate that the 
presentation mode and diversity of Neu5Gc-glycans are critical for detection of the full collection 
of human serum anti-Neu5Gc IgGs.
Introduction
Carbohydrates are major biomolecules that play key structural and functional roles, such as 
affecting protein folding and trafficking, involved in cell recognition, development, and 
signaling.1,2 Carbohydrate chains (glycans) either free or conjugated to proteins and lipids 
decorating the surfaces of all living cells are potential candidates or targets for diagnostics 
and therapeutics.3–5 However, antibodies targeting glycan determinants commonly have low 
affinity and some have mixed specificities in comparison to antibodies targeting proteins.
4,6,7 Glycan density, valency, and flexibility could affect antiglycan antibodies binding 
characteristics.8–10 In fact, binding of two or more carbohydrate determinants could result in 
antibodies of higher avidity and specificity,10 and such interactions rely on antigen density 
for optimal spacing and orientation. Several studies investigated the importance of glycan 
density for avidity and selectivity of antibodies and lectins in a variety of controllable 
multivalent systems.11–16 For example, modulation of glycan densities on a carrier protein 
(e.g., bovine serum albumin or BSA) revealed different binding patterns of serum antibodies,
9 and similarly affected binding preferences of antibodies and lectins against dendrimers17 
and synthetic polymer13 with different glycan densities.
There are diverse anticarbohydrate antibodies in human serum, some involved in human 
health (e.g., blood group antibodies, anti-Gal).18–20 Likewise, incorporation of the dietary 
nonhuman sialic acid, N-glycolylneuraminic acid (Neu5Gc), into human glycans results in a 
polyclonal serum anti-Neu5Gc response that targets diverse Neu5Gc-glycoconjugates.21 
Circulating serum antibodies against Neu5Gc-containing structures have been suggested to 
contribute to chronic inflammation-related diseases in humans,3,22–25 some of which were 
observed in a dose-dependent manner.26–28 Moreover, the levels of circulating human anti-
Neu5Gc antibodies could potentially be used to assess patients clinical condition.23,29,30 
However, detection and quantification of human serum anti-Neu5Gc IgGs are challenging 
due to the high diversity of Neu5Gc-containing epitopes and resulting humoral responses.
We aimed to evaluate how different presentation modes of Neu5Gc-glycans can affect the 
detection of anti-Neu5Gc IgGs in human serum. Current methods include enzyme-linked 
immunosorbent assay (ELISA) and sialoglycan microarray displaying selected synthetic or 
natural targets.21,29,31,32 Here, we compare serum IgG recognition of Neu5Gc-containing 
glycoproteins, glycopeptides, and synthetic glycans. Our results demonstrate that the 
presentation mode and diversity of Neu5Gc-glycans are critical for detection of human 
serum anti-Neu5Gc IgGs.
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Preparation and Characterization of Sialo-Glycopeptides
To generate sialo-glycopeptides (GPs), serum from wild-type (WT; Neu5Gc-positive) or 
Cmah-knockout (Cmah-KO; Neu5Gc-negative) mice were collected and digested with 
Pronase protease, a mixture of endopeptidases and exopeptidases, to yield GPs and free 
amino acids (Figure 1).33 Digestion was allowed to proceed for 5 days with daily addition of 
fresh Pronase to ensure complete breakdown of serum sialo-glycoproteins. Progression of 
digestion was monitored by silver staining and showed that after 3 days most proteins had 
been digested (Figure 2A). Yet, according to 1,2-diamino-4,5-methylenedioxybenzene-high 
performance liquid chromatography (DMB-HPLC) analysis, the Sia content had not been 
altered throughout the 5 days of digestion (Figure 2B). Free amino acids were separated 
from the digested GPs by 3 kDa centrifugal filters, with minimal loss of sialylated GPs in 
the run-through (Figure 3A). To further characterize Sia type and linkage, the resulting GPs 
were coated onto ELISA plates and examined by chicken anti-Neu5Gc IgY, and the Sia-
specific lectins SNA (binds α2-6-linked Sia) and MAL-2 (binds α2-3-linked Sia). GPs 
prepared from WT mice sera contained Neu5Gc (Neu5Gcpos-GP) and both Siaα2-3/6-linked 
glycoconjugates (Figure 3B), consistent with data obtained for undigested WT mouse sera 
glycoproteins.29 GPs obtained from Cmah-KO mice sera lacked Neu5Gc expression 
(Neu5Gcneg-GP), but showed similar detection of Siaα2-3/6-linked glycoconjugates that 
contained only Neu5Ac (data not shown). Importantly, mild periodate treatment of the 
coated GPs abolished antibody/lectins binding (Figure 3B), demonstrating their Sia-specific 
recognition (mild periodate treatment would truncate the Sia side chain at carbons C8 and 
C9, leaving a terminal hydroxyl at C7 while maintaining the carboxylate on C1).34
Optimizing Reproducible Detection of Serum anti-Neu5Gc IgGs Using Sialo-Glycopeptides
Establishing minimal batch-to-batch variability is critical for further use of digested GPs, 
hence separate batches were examined as ELISA targets (Figure 4). We evaluated 
reproducibility of human serum IgG binding to Neu5Gcpos-GPs coated onto 96-well plates 
either according to their protein content (determined by BCA assay) or according to their Sia 
content (determined by DMB-HPLC). Initially, to determine optimal coating concentration 
for maximal detection of serum binding, GPs were coated at serial dilutions (Figure 4). 
There was similar serum binding against GPs coated at 0.25−2 μg protein/well (Figure 4A); 
however, when coated at 75−600 pmol Sia/well, maximal binding occurred at 150 or 300 
pmol Sia/well (Figure 4B). Subsequently, we examined serum binding to four different 
batches of GPs preparations coated with the selected optimal concentrations to yield 
maximal signal at the lowest possible concentration (either 0.25 μg protein/well or 150 pmol 
Sia/well). Analysis of five different sera samples showed that when GPs were coated 
according to protein content there was variable serum IgG binding to different GPs batches 
(Figure 4C). However, when GPs were coated according to Sia content there was 
reproducible serum binding, across all five human sera samples against different batches of 
GPs preparations (Figure 4D). Thus, running ELISA assay with sialylated GPs-target 
coating according to Sia concentration resulted in a reproducible human serum IgG binding.
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Subsequently, four human serum samples with expected high, medium, or low anti-Neu5Gc 
IgG reactivity were examined by ELISA against Neu5Gcpos-GPs coated targets, with or 
without preabsorption with serially diluted Neu5Gcpos-GPs (0.25−0.03 mM Sia). All human 
serum samples showed maximal inhibition already at the lowest concentration of 0.03 mM 
GPs (Figure 5A). Of note, maximal inhibition readout did not reach absolute zero despite the 
fact that the coated target and inhibitor were identical, suggesting that antibody recognition 
of GPs against surface-coated targets is slightly higher than free GPs. For specific detection 
of serum anti-Neu5Gc IgGs using GPs, 28 human serum samples were examined against 
Neu5Gcpos-GPs coated plates with or without preabsorption with Cmah-KO sialo-
glycoproteins (of mouse serum selected to lack mouse-anti-human IgG reactivity29), or with 
0.03/0.06 mM Neu5Gcpos-GPs (Figure 5B). Preabsorption with Cmah-KO sialo-
glycoproteins aimed to remove any human-anti-mouse reactivity; however, it did not inhibit 
human serum IgG binding (Figure 5B), suggesting that the digestion process was efficient at 
removing such potential background reactivity. Furthermore, in all examined human sera, 
free Neu5Gcpos-GPs (either 0.03 or 0.06 mM) significantly inhibited reactivity, but did not 
abolish it completely (Figure 5A,B). To estimate specific human anti-Neu5Gc IgGs 
reactivity, the binding signal of human sera IgGs against Neu5Gcpos-GP (GP assay) was 
used as the maximal signal, from which the minimal signal after inhibition with 0.03 mM 
Neu5Gcpos-GPs was deducted (GP ELISA Inhibition Assay; GP-EIA; Figure 5C). While the 
absolute anti-Neu5Gc IgG value was slightly lower in the GP-EIA, there was a very strong 
correlation between GP versus GP-EIA signals (R2 = 0.977; Figure 5D). Hence, using 
Neu5Gcpos-GPs as targets in ELISA (GP assay) seemed to provide a good estimate for anti-
Neu5Gc IgGs reactivity in human serum, and it was similar to the specific reactivity 
calculated after deducting the inhibition with free GPs (GP-EIA).
Comparing Different Methods for Detection of Human Serum anti-Neu5Gc IgGs
Mouse sera sialo-glycoproteins or their resulting digested sialo-glycopeptides are expected 
to contain identical glycans. Nevertheless, there was a clear difference between the 
recognition of serum IgG against whole (WT) versus digested glycoproteins (Neu5Gcpos-
GPs) in 39 human sera samples (Figure 6A,B). This could result from background human 
anti-mouse reactivity against mouse glycoproteins in the examined human sera samples. 
However, comparison of the more specific assays for detection of human anti-Neu5Gc IgGs 
revealed a similar lack of correlation between either EIA (plates coated with WT 
glycoproteins and preabsorption of human serum against Cmah-KO29) versus GP-EIA 
(plates coated with Neu5Gcpos-GPs with preabsorption of human serum against Neu5Gcpos-
GPs) (Figure 6C,D). Thus, despite the fact that identical glycan structures are presented in 
both assays, it seems that different populations of anti-Neu5Gc IgGs in human sera are 
detected by the different assays. The major difference between the coating Neu5Gc-
glycoproteins versus the digested Neu5Gcpos-GPs is in their mode of presentation, where the 
glycans are found much closer and densely packed in the digested glycopeptides rather than 
on the native glycoproteins.
Another method for detection of anti-Neu5Gc IgGs in human sera is by a sialoglycan 
microarray. In this method, a collection of individual Neu5Gc-glycans with a terminal 
primary amine are each covalently conjugated onto epoxide-coated slides allowing a more 
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detailed analysis of the different pools of anti-Neu5Gc IgGs in human serum.32,34 Eleven 
human serum samples were examined on a sialoglycan microarray revealing the diversity in 
anti-Neu5Gc IgGs in different donors ranging from high-medium-low reactivity, against 
different Neu5Gc-glycans (Figure 7A). While there was a lack of correlation between EIA 
and GP-EIA (Figure 7B, Figure 6D), there was a strong correlation between the average 
anti-Neu5Gc IgGs response on the array in each human serum sample to the response 
revealed by the EIA (Figure 7B,D), and lack of correlation between the array and GP-EIA 
(Figure 7C). In this array format, di-, tri-, or tetra-saccharides are presented in each spot in a 
highly dense manner (100 μM each glycan per ~70 nm spot),32 yet each spot is dedicated to 
a specific glycan. This is in contrast to the densely packed Neu5Gcpos-GPs that contain a 
heterogeneous mixture of glycans. Hence the GP-EIA assay is likely detecting only a 
fraction of the serum anti-Neu5Gc IgGs. Other studies also suggest that the three-
dimensional organization of glycans and their spatial organization could affect antibody 
recognition.34–36 Antibody binding could be enhanced or rather reduced by different 
presentation modes of glycan epitopes,7,34,37,38 and “clustered saccharide patches” of 
multiple glycans in close proximity have important biological roles.35,36
Conclusions
Our findings highlight the importance of glycans’ density and composition (homogeneous/
heterogeneous) in defining anti-carbohydrate antibody recognition. Here we used the diverse 
and polyclonal anti-Neu5Gc IgGs response in human sera to demonstrate how the 
presentation mode of glycans can dramatically affect anti-carbohydrate antibody 
recognition. In this case, the GP-EIA assay could only detect a fraction of the circulating 
anti-Neu5Gc IgGs. In contrast, the array provided a more holistic view of the response and, 
when averaged, seemed comparable with the simpler EIA assay that involves a mixture of 
Neu5Gc glycoproteins. Such insights could be important for understanding the biology and 
implications of this response in humans, given the importance of anti-Neu5Gc antibodies in 
cancer, xenotransplantation, autoimmunity and biotherapeutics.3,22–25,39,40
Materials and Methods
Human Sera Samples
Human sera were obtained from the Israeli Blood Bank and used in accordance with the 
Helsinki Declaration and Tel Aviv University Institutional Review Board.
Mice
Wild-type (WT) and Cmah−/− (Cmah-KO) mice41 were bred in a congenic C57BL/6 
background and maintained according to the Tel Aviv University Institutional Animal Care 
and Use Committee guidelines for laboratory animals.
Antibodies and Lectins
Affinity-purified polyclonal chicken anti-Neu5Gc IgY (Biolegend), horseradish peroxidase 
(HRP)−streptavidin, HRP−goat-anti-human IgG, HRP−AffiniPure donkey-anti-chicken IgY 
(IgG) (H+L), HRP-Streptavidin, and Cy3−goat-anti-human IgG (H+L) (Jackson 
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ImmunoResearch), HRP−goat-anti-human IgG (Bio-Rad), biotinylated SNA (Sambucus 
nigra), and biotinylated MAL-II (Maackia amurensis lectin II) (Vector Laboratories).
Generating Glycopeptides by Digestion of Mouse Sera
WT or Cmah-KO mouse serum (80 mg) was diluted in 8 mL of 0.1 M Tris-HCl pH 8.0 with 
10 mM CaCl2, and then filter sterilized. Pronase solution (Calbiochem; 10 mg/mL in 
distilled water) was incubated at 60 °C for 30 min to inactivate any contaminating sialidase 
activity, then filter sterilized. To initiate serum digestion, 500 μL of sterile Pronase solution 
was added to 9 mL sterile serum solution and the mixture was incubated at 37 °C for 5 days, 
with daily additions of 250 μL sterile Pronase. To examine progress of digestion, 40 μL 
aliquots were collected prior to addition of Pronase (Day 0) and every 24 h. After 5 days, 
Pronase digest was separated on 3 kDa Amicon filters, at 4700 rpm for 1 h at 4 °C. The 
glycopeptides containing upper solution (GP) was stored at 4 °C until used.
Silver Staining
Samples of mouse serum digest (25 μL/day) were dissolved in 20% sample buffer (0.35 M 
Tris pH 6.8, 10.4% SDS, 30% glycerol, 0.6 M DTT, 0.0012% bromophenol blue), then 
boiled at 100 °C for 5 min. Samples (15 μL/lane) were separated on 12.5% SDS-PAGE, then 
gel transferred to freshly prepared fixation buffer (10% acetic acid, 40% ethanol, 0.0185% 
formaldehyde, and 50% water) and incubated for 20 min. The gel was washed with 50% 
ethanol 3 times for 10 min each, then incubated in 0.02% Na2S2O3 in water for 1 min. The 
gel was washed 3 times with water for 20 s each, then incubated in silver solution (9.4 mM 
AgNO3, 0.02% Formaldehyde in water) for 12 min. The gel was washed 3 times with water 
20 s each, then incubated in fixation buffer 2 (0.0005% Na2S2O3, 0.015% Formaldehyde, 
0.47 M Na2CO3 in water). When staining had developed, gel was transferred to a new 
container with stopping solution (10% acetic acid, 40% ethanol and 50% water).
DMB-HPLC Sia Analysis
To quantitate Sia, these were released from glycoconjugates by acid hydrolysis using 0.1 N 
NH2SO4 for 1.5 h at 80 °C, then neutralized with 0.1 N of NaOH. Released Sias were then 
derivatized with 1,2-diamino-4,5-methylenedioxybenzene (DMB; Sigma) for 2.5 h at 50 °C, 
separated by Microcon-10 centrifugal filters and analyzed by fluorescence detection by 
reverse-phase high-pressure liquid chromatography (DMB-HPLC) (Hitachi HPLC, 
Chromaster), on C18 column (Phenomenex C18 Gemini 250 × 4.6 mm) at 24 °C in running 
buffer (84.5% ddH2O, 8.5% acetonitrile, 7% methanol (Merck) for 60 min (min) at a flow 
rate of 0.9 mL/min. Quantification of Sia was carried out by comparison with known 
quantities of DMB-derivatized Neu5Ac.42
Enzyme-Linked Immunosorbent Assay (ELISA)
We tested binding of human serum and lectins to mouse serum glycoconjugates and GPs by 
ELISA. Costar 96-well were coated overnight at 4 °C with 1 μg/well of WT pooled mouse 
sera (lacking mouse-anti-human IgG) or 150 pmol/well GP in coating buffer (50 mM 
sodium carbonate-bicarbonate buffer, pH 9.5). Wells were blocked for 2 h at RT with 
blocking buffer (PBS pH 7.3, 1% chicken ovalbumin (Sigma); PBS/OVA). After removal of 
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buffer, human sera (diluted 1:100 in PBS/OVA) or lectins (0.1 mg/mL Bio-SNA, 4 mg/mL 
Bio-MAL-1, 4 mg/mL Bio-MAL-2) were added to triplicate wells at 100 μL/well then 
incubated at RT for 2 h. Wells were washed three times with PBST (PBS pH 7.3, 0.1% 
Tween-20), detection antibody was then added (100 μL/well, 1:7000 HRP-goat-anti-human 
IgG or 1:10 000 HRP-streptavidin (0.1 mg/mL) diluted in PBS) and incubated for 1 h at RT. 
After washing three times with PBST, wells were developed with 0.5 mg/mL O-
phenylenediamine in citrate-PO4 buffer, pH 5.5, reaction was stopped with H2SO4 and 
absorbance was measured at a 490 nm wavelength on a SpectraMax M3 (Molecular 
Devices).
Mild Periodate Treatment to Determine Sia Specificity
Binding of human sera, lectins, or antibodies to tissue homogenates was tested by ELISA as 
described.21 Costar 96-well plates were coated overnight at 4 °C with mouse sera at 
saturating concentration (1 μg/well) of WT/Cmah-KO pooled mouse sera or (150 pmol/well) 
GP. Next, wells were decanted and freshly prepared periodate solution (cold 2 mM sodium 
metaperiodate in PBS pH 6.5, 200 μL/well) was added followed by gentle shaking for 20 
min at 4 °C in the dark. The reaction was stopped by addition of 50 μL/well of freshly 
prepared 100 mM sodium borohydride in PBS pH 6.5 (final concentration of 20 mM) 
followed by 10 min incubation at RT with gentle shaking (the borohydride inactivates the 
periodate). Concurrently, as a mock control, periodate and borohydride solutions were 
premixed at the same ratio (4:1) and wells incubated (250 μL/well) side-by-side with the 
periodate treated wells. To remove resulting borates, wells were washed three times (10 min 
each wash) with cold wash buffer (50 mM sodium acetate pH 5.5, 100 mM NaCl), then three 
times with PBS pH 7.3. Subsequently, wells were further processed as described (ELISA 
assay).
ELISA Inhibition Assay (EIA)
Anti-Neu5Gc IgGs were evaluated by an ELISA using mouse serum glycoproteins as 
coating targets as described.29 Briefly, Costar 96-well were coated overnight at 4 °C with 1 
μg/well WT pooled mouse sera (lacking mouse-anti-human IgG) in coating buffer (50 mM 
sodium carbonate-bicarbonate buffer, pH 9.5). Wells were blocked for 2 h at RT with 
PBS/OVA (PBS pH 7.3, 1% chicken ovalbumin). During the blocking, human serum was 
diluted 1:100 in EIA buffer (PBS pH 7.3, 1% chicken ovalbumin and Cmah-KO pooled sera 
that lacks mouse-anti-human reactivity, diluted at 1:4000, thus containing 2.3 μg protein/100 
μL and 57 pmol Sia/100 μL) and incubated on ice for 2 h. Next, PBS/OVA (PBS pH 7.3, 1% 
chicken ovalbumin). During the blocking, human serum was diluted 1:100 in EIA buffer 
(PBS pH 7.3, 1% chicken ovalbumin and Cmah-KO pooled sera that lacks mouse-anti-
human reactivity, diluted at 1:4000, thus containing 2.3 μg protein/100 μL and 57 pmol 
Sia/100 μL) and incubated on ice for 2 h. Next, PBS/OVA was removed from wells and 
preincubated human serum was added to triplicate wells at 100 μL/well, then incubated at 
RT for 2 h. Wells were washed three times with PBST (PBS pH 7.3, 0.1% Tween-20), 
detection antibody was then added (100 μL/well, 1:7000 HRP-goat-anti-human IgG diluted 
in PBS) and incubated for 1 h at RT. After washing three times with PBST, wells were 
developed with 0.5 mg/mL O-phenylenediamine in citrate-PO4 buffer, pH 5.5, reaction was 
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stopped with H2SO4, and absorbance was measured at a 490 nm wavelength on a 
SpectraMax M3 (Molecular Devices).
Glycopeptides ELISA Inhibition Assay (GP-EIA)
We tested human serum binding specifically to Neu5Gcpos-GPs by GP-EIA. Costar 96-well 
were coated overnight at 4 °C with saturating concentration (150 pmol Sia/well). 
Neu5Gcpos-GPs in coating buffer (50 mM sodium carbonate-bicarbonate buffer, pH 9.5). 
Wells were blocked for 2 h at RT with PBS/OVA (PBS pH 7.3, 1% chicken ovalbumin). 
During the blocking, human serum was diluted 1:100 in GP-EIA buffer (PBS pH 7.3, 1% 
chicken ovalbumin and serial dilution of Neu5Gcpos-GPs) and incubated on ice for 2 h. 
Next, PBS/OVA was removed from wells and pretreated human serum was added to 
triplicate wells at 100 μL/well then incubated at RT for 2 h. Subsequently, wells were further 
processed as described (ELISA/EIA assay).
Sialoglycan Microarray Fabrication
Arrays were fabricated with NanoPrint LM-60 Microarray Printer (Arrayit) on epoxide-
derivatized slides (Corning) with 16 subarray blocks on each slide. Glycoconjugates were 
distributed into 384-well source plates using 4 replicate wells per sample and 8 μL per well 
(Version 2). Each glycoconjugate was prepared at 50 μM in an optimized print buffer (300 
mM phosphate buffer pH 8.4, supplemented with 0.005% Tween-20). To monitor printing 
quality AlexaFluor-555-Hydraside (Invitrogen, at 2 ng/μL in 178 mM phosphate buffer, pH 
5.5) was used for each printing run. The arrays were printed with four SMP3 pins (5 μm tip, 
0.25 μL sample channel, ~100 μm spot diameter; Arrayit), with spot to spot spacing of 275 
μm. The humidity level in the arraying chamber was maintained at about 70% during 
printing. Printed slides were left on arrayer deck overnight, allowing humidity to drop to 
ambient levels (40−45%). Next, slides were packed, vacuum-sealed, and stored at room 
temperature (RT) until used.
Sialoglycan Microarray Binding Assay
Slides were developed and analyzed as previously described,32 with some modifications. 
Slides were rehydrated with ddH2O and incubated for 30 min in a staining dish with 50 °C 
prewarmed ethanolamine (0.05 M) in Tris-HCl (0.1 M, pH 9.0) to block the remaining 
reactive epoxy groups on the slide surface, then washed with 50 °C prewarmed ddH2O. 
Slides were centrifuged at 200 × g for three min then fitted with ProPlate Multi-Array 16-
well slide module (Invitrogen) to divide into the subarrays (blocks). Slides were washed with 
PBST (0.1% Tween 20), aspirated, and blocked with 200 μL/subarray of blocking buffer 
(PBS/OVA, 1% w/v ovalbumin, in PBS, pH 7.3) for 1 h at RT with gentle shaking. Next, the 
blocking solution was aspirated and 100 μL/block of 1:100 diluted sera diluted in PBS/OVA 
were incubated with gentle shaking for 2 h at RT. Slides were washed three times with 
PBST, then with PBS for 2 min. Bound antibodies were detected by incubating with 
secondary detection diluted in PBS, 200 μL/block at RT for 1 h, Cy3-anti-human IgG 1.2 
μg/mL (Jackson Immunoresearch). Slides were washed three times with PBST, then with 
PBS for 10 min, followed by removal from ProPlate Multi-Array slide module and 
immediately dipping in a staining dish with ddH2O for 10 min with shaking, then 
centrifuged at 200 × g for 3 min, and scanned immediately.
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Processed slides were scanned and analyzed as described at 10 μm resolution with a 
Genepix 4000B microarray scanner (Molecular Devices) at 350 gain. Image analysis was 
carried out with Genepix Pro 6.0 analysis software (Molecular Devices). Spots were defined 
as circular features with a variable radius using with local background subtraction.
Statistical Analysis
Statistical analysis conducted with Prism 6 with the specific methods as indicated in the 
figure legends.
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Generating glycopeptides (GP) from mouse serum. Schematic diagram of method. Mouse 
serum was collected, then digested with Pronase and GPs purified.
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Characterization of Pronase digest. Mouse serum with total 80 mg protein was used per 
digestion. (A) 12.5% gel was loaded with serum digest at 2.5 μg/lane (lanes 1,2,4,6,8,10), 5 
μg/lane (lanes 3,5,7,9,11), or 6 μg of Pronase (lane 12), then daily protein digestion was 
evaluated by silver staining (protein quantified by BCA assay). (B) Total sialic acid content 
in Pronase digest (15 μL) was analyzed daily by DMB-HPLC, showing no significant loss 
during digestion (representative of at least two independent experiments; mean ± SEM).
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Characterization of Sia in glycopeptides. (A) Pronase digest was separated by size though 
Amicon 3 kDa filters, and Sia content quantified by DMB-HPLC (top fraction contains most 
GPs; bottom fraction runthrough, RT, shows minimal Sia loss). (B) Qualitative 
characterization of Sia in GPs from WT mouse sera by ELISA (coated at 1 μg/well protein) 
confirmed presence of Neu5Gc (by anti-Neu5Gc-IgY), and demonstrated Siaα2-6 (SNA) 
and Siaα2-3 (MAL-II) GP-glycoconjugates. Antibody/lectins signal was dramatically 
reduced after mild periodate treatment (that cleaves C8–C9 in side chain of Sia), 
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demonstrating their Sia specific-recognition (representative of two independent experiments; 
mean ± SD of triplicates).
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Evaluating reproducibility of human serum IgG reactivity against Neu5Gcpos-GPs by 
ELISA. (A,B) 96-well Costar plates were coated with Neu5Gcpos-GPs in several 
concentrations based on protein (A; BCA) or Sia (B; DMB-HPLC) content, then binding of 
human serum IgG (SV7) was evaluated by ELISA. (C,D) 96-well Costar plates were coated 
with optimal Neu5Gcpos-GPs 0.25 μg protein/well (C) or 150 pmol Sia/well (D) from four 
different GPs batches, then reproducibility of recognition by human serum IgG was 
evaluated by ELISA with several samples (serum diluted 1/100). Batch-to-batch variability 
was minimal when plates were coated according to Sia content (representative of two 
independent experiments; mean ± SD of triplicates).
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Evaluating specific detection of human serum anti-Neu5Gc IgGs by ELISA against 
Neu5Gcpos-GPs. (A) 96-well Costar plates were coated with Neu5Gcpos-GPs, then binding 
of human serum IgG (diluted 1/100) was evaluated by ELISA, either as is (0), or after 
preincubation with competing Neu5Gcpos-GPs (0.03−0.25 mM Sia). This demonstrated 
specific anti-Neu5Gc IgG reactivity in all samples, and signal was maximally inhibited 
already at 0.03 mM Sia. (B) 28 human serum samples were examined (at 1/100 dilution) by 
ELISA against coated Neu5Gcpos-GPs, either as is (0) or after preincubation with Cmah-KO 
mouse sera (1/4000) or Neu5Gcpos-GPs (0.03 mM and 0.06 mM). The Cmah-KO sera did 
not absorb any human serum reactivity, while Neu5Gcpos-GPs at both concentrations 
inhibited most reactivity (One-Way ANOVA). (C) Anti-Neu5Gc IgGs specific reactivity was 
calculated by deducting the signal obtained after preincubation with 0.03 mM Neu5Gcpos-
GPs from the signal with no inhibition (glycopeptides ELISA inhibition assay; GP-EIA). (D) 
Comparing the human serum reactivity against Neu5Gcpos-GPs as is (GP) versus the GP-
EIA signal showed strong correlation (Pearson r = 0.977). (Representative of at least two 
independent experiments for A-D; mean ± SD of triplicates.)
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Human sera anti-Neu5Gc IgGs detection against mouse sera sialo-glycoproteins versus 
sialo-glycopeptides. (A) 96-well Costar plates were coated either with Neu5Gcpos-GPs (150 
pmol/well) or undigested WT mouse serum (1 μg/well; selected to be negative for mouse-
anti-human IgG reactivity), then binding of 39 human sera samples was evaluated by 
ELISA, detected by HRP-anti-human IgG (Representative of two independent experiments; 
mean ± SD of duplicates). (B) Comparing human sera IgG reactivity against Neu5Gcpos-GP 
or undigested WT mouse serum shows no correlation (Pearson r = 0.036). (C) Anti-Neu5Gc 
IgG reactivity in 11 human sera samples (expected to have high/medium/low reactivity) 
were evaluated either by EIA or GP-EIA. In EIA assay,29 undigested WT mouse serum (1 
μg/well; selected to be negative for mouse-anti-human IgG reactivity) was coated to 96-well 
plates, then examined with human serum samples (diluted 1/100) that were preincubated 
with Cmah-KO mouse sera (1/4000; to absorb human anti-mouse reactivity). In GP-EIA 
assay, the plates were coated with Neu5Gcpos-GP, and human sera preincubated with 
Neu5Gcpos-GP (0.03 mM). Representative of at least two independent experiments; mean ± 
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SD of duplicates). (D) Comparing specific anti-Neu5Gc IgG signal obtained with EIA 
versus GP-EIA showed lack of correlation (Pearson r = 0.034).
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Comparison of human serum anti-Neu5Gc IgG reactivity analyzed by sialoglycan 
microarray versus EIA and GP-EIA. (A) Sialoglycan microarray analysis of sera from 
healthy donors (diluted 1/100). Relative fluorescent units (RFU) are presented as a heatmap. 
(B−D) Correlation analysis of anti-Neu5Gc IgG reactivity obtained by GP-EIA and EIA 
versus sialoglycan microarray (average of all Neu5Gc-glycans per serum sample). (C) No 
correlation between anti-Neu5Gc IgG antibody reactivity between GP-EIA and sialoglycan 
microarray (Pearson r = 0.098). (D) Strong correlation observed between anti-Neu5Gc IgG 
antibody levels between EIA and sialoglycan microarray (Pearson r = 0.905).
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